Investments and Fair Value Measurements - Narrative (Details)					1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 20, 2020 USD ($)	Jan. 02, 2020 USD ($)	Apr. 25, 2019 USD ($)	Nov. 01, 2018 USD ($) $ / shares	Mar. 02, 2020 USD ($)	Mar. 29, 2020 USD ($)	Dec. 29, 2019 USD ($)	Jan. 03, 2021 USD ($) venture	Dec. 29, 2019 USD ($)	Dec. 30, 2018 USD ($)	Feb. 10, 2021 USD ($)	Jul. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities							$ 106,000,000	$ 376,000,000	$ 106,000,000
Marketable equity securities unrealized losses and gains								270,000,000	53,000,000	$ 21,000,000
Strategic equity investments, without readily determinable fair values							220,000,000	314,000,000	220,000,000
Equity method investments							53,000,000	104,000,000	53,000,000
Gains on deconsolidation								0	54,000,000	0
Loss on derivative assets related to terminated acquisition								116,000,000	8,000,000	$ 0
PacBio
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash payments				$ 1,200,000,000	$ 34,000,000	$ 132,000,000	18,000,000
Share price (in dollars per share) | $ / shares				$ 8.00
PacBio a termination fee		$ 98,000,000
PacBio will pay cash termination fee		52,000,000
Equity or debt financing to be raised		$ 100,000,000
Derivative assets related to terminated acquisition							10,000,000	40,000,000	10,000,000
PacBio | Selling, general and administrative
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loss on derivative assets related to terminated acquisition								(92,000,000)	(8,000,000)
PacBio | Other Operating Income Expense
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loss on derivative assets related to terminated acquisition								25,000,000
GRAIL, Inc
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments to acquire additional investments								60,000,000
Cash payments	$ 3,500,000,000
Principal amount of notes outstanding	$ 1,000,000,000
SB Northstar LP | Subsequent Event
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
PacBio will pay cash termination fee											$ 52,000,000
Helix Holdings I, LLC
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent value right, terms			7 years
Gains on deconsolidation			$ 39,000,000
Contingent value right			$ 30,000,000
Unrealized gain (loss) from contingent value right								$ 7,000,000	$ (1,000,000)
Helix Holdings I, LLC | Variable Interest Entity, Primary Beneficiary
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Absorbed Helix's losses percentage									50.00%	50.00%
PacBio | SB Northstar LP | Subsequent Event | Convertible Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal amount of notes outstanding											$ 900,000,000
Venture Capital Investment Fund (the Fund)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of venture capital investment funds | venture								2
Commitment in new venture capital investment fund								$ 100,000,000
Remaining capital commitment								35,000,000
Second Venture Capital Investment Fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commitment in new venture capital investment fund								160,000,000
Remaining capital commitment								140,000,000
Investee
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Revenue from transactions with strategic investees								62,000,000	$ 71,000,000	$ 143,000,000
GRAIL, Inc | Variable Interest Entity, Not Primary Beneficiary
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net assets							$ 190,000,000	$ 250,000,000	$ 190,000,000
Helix Holdings I, LLC | Variable Interest Entity, Primary Beneficiary
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity ownership interest percentage												50.00%